Suppr超能文献

[淋巴结阴性乳腺癌患者术后辅助治疗的指征]

[The indications for postoperative adjuvant therapy in node-negative breast cancer patients].

作者信息

Asagoe T, Hanatani Y, Doi M, Miyoshi H, Hasumi T, Nagaoka N, Hanashi T, Kodaira S

机构信息

The 1st Department of Surgery, Teikyo University School of Medicine, Japan.

出版信息

Gan To Kagaku Ryoho. 1996 Feb;23(3):311-6.

PMID:8712824
Abstract

A clinicopathological study on prognosis has been carried out in 233 breast cancer patients with more than twenty inspected nodes and without lymph node metastasis. Multivariate analysis of clinicopathological findings in node-negative breast cancers showed that the best combination of clinical features predicting prognosis were age, menstruation status, tumor location and tumor diameter; and from 11 pathological features, three factors (histological type, histological grade and the grade of tumor infiltrating lymphocytes) were selected under condition of p<0.05. With solid-tubular carcinoma, histological grade III and negative tumor infiltrating lymphocytes as the 3 poor prognostic factors, node-negative breast cancers were classified. The recurrence rates of subgroups with the number of 3, 2, 1 and 0 were 28%, 16%, 7% and 0%, respectively. We conclude that the grade of tumor infiltrating lymphocytes is especially significant as the prognostic factor in node-negative breast cancers, and that postoperative adjuvant chemoendocrine therapy must be performed for patients with node-negative breast cancer with more than two poor prognostic pathological factors.

摘要

对233例有20个以上检查淋巴结且无淋巴结转移的乳腺癌患者进行了预后的临床病理研究。对淋巴结阴性乳腺癌的临床病理结果进行多因素分析显示,预测预后的最佳临床特征组合为年龄、月经状况、肿瘤位置和肿瘤直径;在11项病理特征中,在p<0.05的条件下选择了3个因素(组织学类型、组织学分级和肿瘤浸润淋巴细胞分级)。以实性-管状癌、组织学III级和肿瘤浸润淋巴细胞阴性作为3个不良预后因素,对淋巴结阴性乳腺癌进行分类。3个、2个、1个和0个不良预后因素亚组的复发率分别为28%、16%、7%和0%。我们得出结论,肿瘤浸润淋巴细胞分级作为淋巴结阴性乳腺癌的预后因素尤为重要,并且对于具有两个以上不良预后病理因素的淋巴结阴性乳腺癌患者必须进行术后辅助化疗和内分泌治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验